Resources from the same session
Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
Presenter: Byoung Chul Cho
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Invited Discussant – Asian perspectives on Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
Presenter: Bin-Chi Liao
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Invited Discussant – Asian perspectives on POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (C-P) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy
Presenter: Krittiya Korphaisarn
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
Presenter: Masatoshi Kudo
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Q&A and discussion
Session: ESMO 2024 Highlights session 1
Resources:
Webcast